A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502686-24-00

Acronym

56021927PCR3020

Enrollment

Registered

2023-09-25

Start date

2023-11-22

Completion date

Unknown

Last updated

2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Brief summary

- 18-month radiographic progression-free survival rate. Radiographic progression will be assessed by investigators using conventional imaging - 18-month percent change in severity adjusted hot flash score

Interventions

DRUGJNJ-56021927

DRUG-

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
- 18-month radiographic progression-free survival rate. Radiographic progression will be assessed by investigators using conventional imaging - 18-month percent change in severity adjusted hot flash score	—

Countries

France, Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026